Neuren Pharmaceuticals IPO - Phase 3 time!

[Joshuatree]

Great close on biggest volume in a while closing @ 13.5c. If it holds great but not banking on it.

[Joshuatree]

5 or 6 year high currently 15.5c after hitting 17c.

Speeding ticket from ASX response "neuren was featured favourably in The AFR on 30th dec and Jan 1 and also in Sydney morning herald and the Age on 29th dec. neuren was selected by the AFR as one of 4 biostocks to watch in 2015"

[Joshuatree]

17c again and looking strong. i sold all my holdings for a little less. HOPE, to get back in before more expected announcements.Its flavour of the moment

[samoooli]

FDA decision due either Tomorrow or Monday - Bit of a run starting on volume maybe?

[Joshuatree]

Not good for NEU in the short term, didn't get the FDA decision they wanted. Can apply again though .Still other irons in the fire. Will watch atp.

[samoooli]

Yeap. Ouch. Sold out at 13 looking for a lower entry..

Way overdone imo - this is not a one trick pony.

[Joshuatree]

PDF

Successful phase 2 trial. s/p up 33% today to 12c. Alas i took my eye off and never got back in.Should help my position a little in the ASX stock pick comp.

[yabster]

Old Thread- interesting reading- anyone on this? - good NZ roots- Dame Margaret Brimble developed the drug- Neuren have partnered with Acadia - for the US rights- FDA has recently approved the drug -for Retts syndrome.

First sales expected in April will trigger a $40m US payment to Neuren, Royalties high also.
ROW rights- in negotiation
NNZ 2591 - in phase II, four other indications- -Oppurtunity- 5 times that of Retts

[Joshuatree]

Sold all mine for re 16c e ,and forgot to get back in at the 13c,now $13.00! You ridden this up yabster or anyone else?

[yabster]

yeah have few first bought at 8.5 cents -but they did a 20:1 consol- bought a few on the way up too. Still worth a look lots of $ coming in and NNZ 2591 is meant to be a better version of Trof - 4 indications in phase II (lots more patented) and 1 will have phase two results later in the year.